Fred Aslan describes what the funds will enable Artiva to do in the clinic, and why he believes the company’s non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions.
Watch the interview here.
NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t...
Artiva’s President and CEO Fred Aslan, M.D., explores how Artiva is reshaping cell therapy with In Vivo. In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Read the full article here (subscription may be required).
DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics, about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both haematological diseases like blood cancer,...